Bioequivalence study of clindamycin phosphate injection (Clinott-P ) in Thai healthy volunteers

Journal of the Medical Association of Thailand

Volumn 89, Issue 5, 2006, Pages 683-689

  Leelarasamee, Amorn ^a   Tatong, Wallapa ^b   Kasattut, Narat ^b   Sriboonruang, Tatta ^b   Ayudhya, Duangchit Panomvana Na ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Bioequivalence study; Clindamycin phosphate

Indexed keywords

CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; CLINOTT P;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD CHEMISTRY; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DELTOID MUSCLE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INJECTION PAIN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CLINDAMYCIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; THAILAND; THERAPEUTIC EQUIVALENCY;

EID: 33646772913     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. LeFrock JL, Molavi A, Prince RA. Clindamycin. Med Clin North Am 1982; 66: 103-20.
2. Klepser ME, Banevicius MA, Quintiliani R, Nightingale CH. Characterization of bactericidal activity of clindamycin against Bacteroides fragilis via kill curve methods. Antimicrob Agents Chemother 1996; 40: 1941-4.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
4. Metzler CM, DeHaan R, Schellenberg D, Vandenbosch WD. Clindamycin dose-bioavail-ability relationships. J Pharm Science 1973; 62: 591-98.
5. Townsend JR, Baker RP. Pharmacokinetic comparison of three clindamycin phosphate dosing schedules. Drug Intell Clin Pharm 1997; 21: 279-81.
6. http://wwwapp1.fda.moph.go.th/be/rule.htm (access date: January 25, 2006).
7. Batzias GC, Delis GA, Koutsoviti-Papadopoulou M. A new HPLC/UV method for the determination of clindamycin in dog blood serum. J Pharm Biomed Anal 2004; 35: 545-54.
8. FDA guidance: statistical procedures for bioequivalence studies using a standard two treatment cross over design. [WWW.document]. Food Drug and Administration. Ministry of Public Health. Thailand, 2005. http://www.app1.fda. moph.go.th/be/rule.htm [access date: December 26, 2005].
9. Cody RL, Slack MK. Crossover design in pharmacy research. Ann pharmacoth 1992;26: 327-33.
10. Mazur D, Schug BS, Evers G, Larsimont V, Fieger-Buschges H, Gimbel W, et al. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. Int J Clin Pharmacol Ther 1999; 37: 386-92.
11. Department of Medical Sciences. Ministry of Public Health. Thailand. (1992). Guidelines for bioavailability/bioequivalence study.
12. US Food and Drug Administration (2001). Statistical approaches to establishing bioequivalence. Rockville, MD.
13. US Food and Drug Administration (1992). Guidance on statistical procedures for bioequivalence using a standard two-treatment crossover design. Rockville, MD.
14. Lewis RE, Klepsler ME, Ernst EJ, Lund BC, Biedenbach DJ, Jones RN. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. Antimicrob Agents Chemother 1999; 43: 2005-9.